Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

March 31, 2008

Study Completion Date

July 31, 2009

Conditions
HemoglobinopathiesSickle Cell DiseaseThalassemia
Interventions
DRUG

Busulfex

Given once daily for 4 days

DRUG

Fludarabine

Given intravenously once daily for 4 days

DRUG

Alemtuzumab

One day before fludarabine and busulfex are started, alemtuzumab will be given once daily for 5 days.

PROCEDURE

Stem Cell Transfusion

Performed three days after the end of chemotherapy

Trial Locations (6)

30322

Winship Cancer Institute-Emory University, Atlanta

43210

Ohio State University College of Medicine, Columbus

71130

Feist-Weiller Cancer Center-LSU, Shreveport

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Emory University

OTHER

collaborator

Feist-Weiller Cancer Center at Louisiana State University Health Sciences

OTHER

collaborator

Ohio State University

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00153985 - Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies | Biotech Hunter | Biotech Hunter